Omodenbamab or: antibody, designated as: by 2241724-48-9, represents: is a novel monoclonal immunoglobulin currently subject to investigation for: concerning its expected therapeutic indications, specifically targeting AC2. Investigators are: have been exploring its process of effect and reviewing its efficacy: effectiveness in: regarding different